Kimberly Kay Leslie (Kimberly K Leslie)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 4

Top Topics

Dna Methylation

Endometrial Cancer

Endoplasmic Reticulum

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Disease markers

Cell death & disease

This page only lists publications with an associated author ORCID identifier.

Publications

Kristina W W Thiel, Eric J Devor, Virginia L Filiaci, David G Mutch, Katherine Moxley, Angeles A Secord, Krishnansu S Tewari, Megan E McDonald, Cara A Mathews, Casey Cosgrove, Summer Dewdney, Carol Aghajanian, Megan I Samuelson, Heather A Lankes, Robert A Soslow, Kimberly Kay Leslie
TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (28) (2022)
Kimberly Kay Leslie, Kristina W W Thiel
Reply to E. Guerra et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Jianling Bi, Yuping Zhang, Paige K Malmrose, Haley A Losh, Andreea M Newtson, Eric J Devor, Kristina W Thiel, Kimberly Kay Leslie
Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer. Cell death & disease 13 (1) (2022)
Xiangbing Meng, Shujie Yang, Yujun Li, Yiyang Li, Eric J Devor, Jianling Bi, Xinhao Wang, Shaikamjad Umesalma, Dawn E Quelle, William H Thiel, Kristina W Thiel, Kimberly Kay Leslie
Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations. Disease markers 2018 (2018)